Homepage
Medication Guide
What are the Indications for Belzutifan (Welireg)?
Belzutifan (Welireg) is an oral hypoxia-inducible factor inhibitor (HIF-2α inhibitor) that received its first approval for marketing in the United States in 2021.What are the Indications for Belzutifa...
510
Sunday, January 4th, 2026, 09:43
Dosage and Administration of Belzutifan (Welireg)
Belzutifan (Welireg) is a hypoxia-inducible factor-2α (HIF-2α) inhibitor that received its first approval in the United States in 2021. It is primarily indicated for the treatment of adult patients wi...
510
Sunday, January 4th, 2026, 09:33
What Are the Precautions for Momelotinib Administration?
Momelotinib is a Janus kinase (JAK) 1 and 2 inhibitor. It is primarily indicated for the treatment of adult patients with anemia associated with intermediate- or high-risk myelofibrosis, whether it is...
516
Wednesday, December 31st, 2025, 10:36
Adverse Reactions of Momelotinib
Momelotinib is a kinase inhibitor indicated for the treatment of adult patients with intermediate- or high-risk primary or secondary myelofibrosis who have anemia. As a potent prescription medication,...
509
Wednesday, December 31st, 2025, 10:31
What Are the Purchase Channels for Erdafitinib (Balversa)?
Erdafitinib (Balversa) is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA), indicated for the treatment of adult patients with locally advanced or metastatic urothelial carci...
509
Wednesday, December 31st, 2025, 10:26
What Are the Indications for Erdafitinib (Balversa)?
Erdafitinib (Balversa) is an oral kinase inhibitor that was first approved in the United States in 2019. It represents a precision therapy option targeting specific genetic alterations, and is primari...
507
Wednesday, December 31st, 2025, 10:21
Dosage and Administration of Erdafitinib (Balversa)
Erdafitinib (Balversa) is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma harbouring susceptible FGFR3 or FGFR2 genetic altera...
512
Wednesday, December 31st, 2025, 10:03
What are the Precautions for Using Seladelpar?
Seladelpar is a novel peroxisome proliferator-activated receptor delta (PPAR-δ) agonist indicated for the treatment of adult patients with primary biliary cholangitis (PBC) who have an inadequate resp...
511
Tuesday, December 30th, 2025, 10:02
Adverse Reactions of Sladelpar
Sladelpar is a novel peroxisome proliferator-activated receptor delta (PPARδ) agonist. Approved in the United States in 2024, it is indicated for the treatment of adult patients with primary biliary c...
508
Tuesday, December 30th, 2025, 09:38
What Are the Purchase Channels for Voranidenib (Voranigo)?
Voranidenib (Voranigo) is a novel targeted therapy approved for marketing by the U.S. Food and Drug Administration (FDA) in 2024. It is indicated for the treatment of grade 2 gliomas (astrocytoma or o...
508
Tuesday, December 30th, 2025, 09:33
28 / 214
2139 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved